Last reviewed · How we verify

Depo-Provera Injectable Product

Ohio State University · FDA-approved active Small molecule Quality 5/100

Depo-Provera Injectable Product, marketed by Ohio State University, is a well-established contraceptive with a strong presence in the market. The key composition patent expires in 2028, providing a significant period of exclusivity and protection against generic competition. The primary risk is the lack of recent key trial results to support ongoing efficacy and safety, which could impact market confidence.

At a glance

Generic nameDepo-Provera Injectable Product
SponsorOhio State University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: